After submitting an application for Class D medical device MDACS registration in Hong Kong, the Local Responsible Person (LRP) and the manufacturer must adhere to specific regulatory obligations, ongoing requirements, and compliance practices to ensure a smooth review process and continued eligibility for listing under the Medical Device Administrative Control System (MDACS).
Below is a comprehensive overview of the regulations and post-submission requirements that must be followed after application submission but before approval, and immediately after approval if granted:
All official communications are handled through the MDIS portal.
The LRP must monitor MDIS regularly for:
Requests for clarification
Additional document requirements
Review status updates
🔹 Action: Respond to any MDD request within the timeframe specified (typically 10–30 calendar days). Failure to respond may result in rejection or administrative closure of the application.
While under review, the following documents must remain valid and current:
Manufacturer’s ISO 13485 certification
Foreign regulatory approvals (e.g., CE/FDA)
Authorized representative appointments (if applicable)
Essential technical documents (must not be altered during review unless disclosed)
🔹 Action: Notify the MDD via MDIS if any document is updated, expired, or reissued during the review period.
Devices under review must not be marketed or distributed in Hong Kong until listing is granted, unless:
An Import Licence is separately obtained under the Pharmacy and Poisons Ordinance (for exceptional access, e.g., hospital tenders).
🔹 Action: Delay all marketing activities, product launches, or sales efforts until MDACS listing is confirmed.
Once the device is listed, the following regulations and responsibilities take effect immediately:
Listing is valid for 5 years.
You must renew the listing before expiration (recommended: at least 6 months in advance).
🔹 Maintain original application documents for audit or renewal.
Ensure the product labeling and Instructions for Use (IFU) meet the requirements outlined in:
GN-07: Guidance Notes for Labeling
Include:
Device name/model
Manufacturer and LRP information
Intended use, warnings, lot/serial numbers
CE/FDA identifiers (if any)
Traditional Chinese and/or English language
🔹 Action: Keep sample labels and packaging on file for inspection.
Comply with GN-10 (Adverse Event Reporting):
Class D devices require mandatory vigilance reporting.
Must report:
Death or serious deterioration of health
Device malfunction that could cause harm
Timeline for submission:
2 calendar days (serious public threat)
10 calendar days (serious deterioration/death)
30 calendar days (other reportable events)
🔹 Action: Maintain an internal AE tracking and reporting system.
You must have a documented system to:
Monitor real-world safety and performance
Analyze user feedback, complaints, and failures
Initiate field corrective actions if necessary
🔹 Refer to ISO 13485:2016 Clause 8.2.1 and local guidance on PMS.
Follow GN-11 (FSCA and Recalls) if:
Product recall is needed
Warnings or usage restrictions are issued
Device requires modification or update
🔹 Action: Notify MDD via MDIS and provide:
Field Safety Notice (FSN)
Root cause analysis
Corrective measures taken
Ensure the manufacturer continues to hold:
Valid ISO 13485 certificate
Active foreign market authorization (e.g., CE, FDA)
🔹 Action: Submit updated certificates or regulatory changes to MDD if applicable.
Maintain:
All technical documents submitted for at least 5 years
Complaint logs, AE reports, recall history
Distribution and sales records
🔹 Action: Ensure the LRP has access to a complete documentation archive for audit.
You must notify MDD in advance of any significant change, such as:
Change of manufacturer or LRP
Product design, indication, or labeling change
Addition of new models or variants
Change in sterilization or software
🔹 Action: Use MDIS to submit supplementary documentation and variation application.
You may reference the listing number as evidence of MDACS inclusion.
Do not misrepresent the listing as official regulatory approval or market authorization.
🔹 Suggested language:
"This product is listed under the Medical Device Administrative Control System (MDACS) by the Hong Kong Department of Health."
MDD may conduct audits or request reassessment of:
Technical documentation
PMS records
Complaint handling
Vigilance activities
🔹 Action: Keep all records accessible and up-to-date.
| Obligation | Timing | Reference |
|---|---|---|
| Respond to MDD queries | During review | – |
| Avoid premature marketing | Pre-approval | GN-01, MDACS Policy |
| Report adverse events | Post-approval | GN-10 |
| Maintain PMS & FSCA plan | Post-approval | GN-11 |
| Update product/firm changes | Ongoing | MDIS |
| Renew listing | Every 5 years | MDACS Listing Renewal |
| Maintain QMS & regulatory approvals | Ongoing | ISO 13485, GHTF recognition |
| Ensure labeling compliance | Post-approval | GN-07 |
| Retain technical documents | Min. 5 years | GN-01/02 |
| Use listing number appropriately | Post-approval | MDACS Guidance |
Would you like a downloadable Post-Approval Regulatory Compliance Checklist or editable templates for AE reports, FSCA notices, or renewal applications? I can provide those based on your device type and regulatory strategy.

Whatsapp or Wechat:+86 15816864648;email address:hito.lin@grzan.cn